Anti-RUNX1 / AML1 抗体

• WB

Unknown

Western blot - Anti-RUNX1 / AML1 antibody (AB35962)

All lanes:

Western blot - Anti-RUNX1 / AML1 antibody (ab35962) at 1 µg/mL

Lane 1:

Jurkat nuclear extract lysate (<a href='/products/unavailable/jurkat-nuclear-extract-lysate-ab14844'>ab14844</a>) at 10 µg

Lane 2:

MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/10000 dilution

Predicted band size: 48 kDa

Observed band size: 47 kDa,52 kDa,54 kDa,55 kDa,75 kDa

true

Exposure time: 10s

• WB

CiteAb

Western blot - Anti-RUNX1 / AML1 antibody (AB35962)

Western Blotting using Anti-RUNX1 / AML1 antibody, ab35962. Publication image from Wang, F. et al., 2017, Nat Commun, 29127290. Legend direct from paper.

KSRP and miR-129 regulate monocytic and granulocytic differentiation in vivo. a A schematic representation of the in vivo experimental design for the transplantation of CD34+ HPCs isolated from cord blood into mice (n = 4). b The CD14+ and CD11b+ populations in BM from mice transplanted with lenti-sh-KSRP or lenti-GFP-transduced HPCs were monitored by FACS. c qPCR analysis of pri-miR-129 and mature miR-129 expression in BM from mice transplanted with the lenti-GFP- or lenti-129-transduced HPCs. d The CD14+ and CD11b+ populations in BM from mice transplanted with lenti-129- or lenti-GFP-transduced HPCs were monitored by FACS. The quantitation is shown in the left panel. e Schematic representation of a model describing the role of the KSRP-miR-129-RUNX1 axis in regulating the normal lineage-specific differentiation of CD34+ HPCs. f qPCR analysis of pri-miR-129 and mature miR-129 expression in BM from mice transplanted with lenti-GFP- or lenti-sh-KSRP-transduced CD34 + HPCs. g Immunoblot of RUNX1 expression in BM from mice transplanted with lenti-129- or lenti-GFP-transduced HPCs. h Immunoblot of KSRP and RUNX1 expression in BM from mice transplanted with lenti-sh-KSRP- or lenti-GFP-transduced HPCs. Data are shown as means±s.d. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test

false

• WB

CiteAb

Western blot - Anti-RUNX1 / AML1 antibody (AB35962)

Western Blotting using Anti-RUNX1 / AML1 antibody, ab35962. Publication image from Wang, F. et al., 2017, Nat Commun, 29127290. Legend direct from paper.

miR-129 targets RUNX1 to modulate myeloid differentiation. a A computational prediction of the conserved binding sites and the designed mutated sequences in these sites within the 3′ UTR of the human RUNX1 mRNA. b Relative luciferase activity of the indicated reporter constructs. PC, positive control. Three technical replicates from a single experiment representative of two independent experiments. c Immunoblot of the endogenous RUNX1 levels in CD34+ HPCs undergoing monocytic or granulocytic differentiation. d Immunoblot of RUNX1 expression in CD34+ HPCs transduced with lenti-129, miRZip-129 or their controls on day 10 of monocytic or granulocytic differentiation. e qPCR of the RUNX1 mRNA levels in CD34+ HPCs transduced with lenti-129, miRZip-129 or their controls during monocytic and granulocytic differentiation. Three technical replicates from a single experiment. f, g CD34+ HPCs were transduced with lenti-RUNX1 or lenti-GFP control for 24 h and then cultured for 15 days to allow the cells to differentiate into monocytes or granulocytes. Quantitation of the Giemsa staining was shown in f and FACS analysis of the CD14+/CD11b+ and CD11b+ populations of GFP-positive cells on day 15 (g). h qPCR analysis of the monocyte-granulocyte markers at the indicated times during monocytic or granulocytic differentiation of RUNX1-overexpressing cells. Three technical replicates from a single experiment. Data are shown as means±s.d. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test

false

• WB

CiteAb

Western blot - Anti-RUNX1 / AML1 antibody (AB35962)

Western Blotting using Anti-RUNX1 / AML1 antibody, ab35962. Publication image from Wang, F. et al., 2017, Nat Commun, 29127290. Legend direct from paper.

KSRP and miR-129 regulate monocytic and granulocytic differentiation in vivo. a A schematic representation of the in vivo experimental design for the transplantation of CD34+ HPCs isolated from cord blood into mice (n = 4). b The CD14+ and CD11b+ populations in BM from mice transplanted with lenti-sh-KSRP or lenti-GFP-transduced HPCs were monitored by FACS. c qPCR analysis of pri-miR-129 and mature miR-129 expression in BM from mice transplanted with the lenti-GFP- or lenti-129-transduced HPCs. d The CD14+ and CD11b+ populations in BM from mice transplanted with lenti-129- or lenti-GFP-transduced HPCs were monitored by FACS. The quantitation is shown in the left panel. e Schematic representation of a model describing the role of the KSRP-miR-129-RUNX1 axis in regulating the normal lineage-specific differentiation of CD34+ HPCs. f qPCR analysis of pri-miR-129 and mature miR-129 expression in BM from mice transplanted with lenti-GFP- or lenti-sh-KSRP-transduced CD34 + HPCs. g Immunoblot of RUNX1 expression in BM from mice transplanted with lenti-129- or lenti-GFP-transduced HPCs. h Immunoblot of KSRP and RUNX1 expression in BM from mice transplanted with lenti-sh-KSRP- or lenti-GFP-transduced HPCs. Data are shown as means±s.d. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test

false

• WB

CiteAb

Western blot - Anti-RUNX1 / AML1 antibody (AB35962)

Western Blotting using Anti-RUNX1 / AML1 antibody, ab35962. Publication image from Wang, F. et al., 2017, Nat Commun, 29127290. Legend direct from paper.

miR-129 targets RUNX1 to modulate myeloid differentiation. a A computational prediction of the conserved binding sites and the designed mutated sequences in these sites within the 3′ UTR of the human RUNX1 mRNA. b Relative luciferase activity of the indicated reporter constructs. PC, positive control. Three technical replicates from a single experiment representative of two independent experiments. c Immunoblot of the endogenous RUNX1 levels in CD34+ HPCs undergoing monocytic or granulocytic differentiation. d Immunoblot of RUNX1 expression in CD34+ HPCs transduced with lenti-129, miRZip-129 or their controls on day 10 of monocytic or granulocytic differentiation. e qPCR of the RUNX1 mRNA levels in CD34+ HPCs transduced with lenti-129, miRZip-129 or their controls during monocytic and granulocytic differentiation. Three technical replicates from a single experiment. f, g CD34+ HPCs were transduced with lenti-RUNX1 or lenti-GFP control for 24 h and then cultured for 15 days to allow the cells to differentiate into monocytes or granulocytes. Quantitation of the Giemsa staining was shown in f and FACS analysis of the CD14+/CD11b+ and CD11b+ populations of GFP-positive cells on day 15 (g). h qPCR analysis of the monocyte-granulocyte markers at the indicated times during monocytic or granulocytic differentiation of RUNX1-overexpressing cells. Three technical replicates from a single experiment. Data are shown as means±s.d. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test

false